GL1X · GenesisL1 explorer

Research workbench

The crystal structure of the T325S mutant of the human holo sepsecs

Analyse The crystal structure of the T325S mutant of the human holo sepsecs in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4ZDL
Type
protein
Length
888 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
O-phosphoseryl-TRNA(SEC) selenium transferase
EC
2.9.1.2
UniProt
Q9HD40
Ligands
PLR
Pockets
4 · best druggability 0.58

Structure

x-ray diffraction · 1 distinct chain · 45% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BO-phosphoseryl-TRNA(SEC) selenium transferase (EC 2.9.1.2)protein44445% helix, 16% strandQ9HD40

Ligands and binding sites

  • PLR · (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl dihydrogen phosphate · ligand · 2 copies · chains A, B
  • FLC · Citrate anion · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13000.580.7749PLR
22790.570.7848PLR
3880.400.7719empty
4730.350.7616empty

Interfaces

1 interface between chains.

  • A–B · 199 Ų buried · 0 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent (covalent ligand).

Compared structures

  • 4ZDL · The crystal structure of the T325S mutant of the human holo SepSecS · the same entry in another collection · chain A against A, TM-score 1.00
  • Q9HD40 · AlphaFold monomer V2.0 prediction for O-phosphoseryl-TRNA(SEC) selenium transferase… · a predicted model of the same protein · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.